Madrid / Barcelona / Helsinki / Philadelphia / Bellinzona / Havana / Milan / /
Company
SPSS Inc. / LoRusso P. Toward / Lee SA / Ligand / Eastern Cooperative Oncology Group / /
Country
Italy / Cuba / Spain / /
Currency
SRG / / /
Event
FDA Phase / /
Facility
Hospital del Mar-Parc de Salut MAR / Center of Molecular Immunology / National Institute of Oncology / Hospital del Mar. / Hospital del Mar / Hospital Clínic / Autonomous University of Barcelona / Institute of Oncology / COOH terminus / / /
IndustryTerm
treatment of a growing number of cancers / Cancer Therapy / Cancer Therapies / evidence-based management / cancer treatment / treatment of locally advanced head and neck cancer / cetuximab binding site / anatomic site / buffered formalin solution / mL saline solution / /
MedicalCondition
total tumor / EGFR-dependent tumors / allergic reaction / inflammatory reaction / cutaneous injury / small cell lung carcinoma / advanced squamous cell carcinoma / cardiac failure / human colorectal cancer / solid tumors / skin rash / J Cancer / high-grade astrocytic tumors / head and neck cancer translational relevance epidermal growth factor receptor ( egfr ) / metastatic breast cancer / induced inflammatory response / inflammatory changes / altered tumor / non-small cell lung cancer / inflammatory cells / breast tumor / advanced epithelial-derived cancer / squamous cell carcinomas / head and neck cancer / squamous cell cancer / MS / advanced breast cancer / breast human tumor / epithelial-derived tumors / head and neck tumor / primary tumors / enhanced skin inflammation / cancers / tumor / III disease / squamous cell carcinoma / advanced gastric carcinoma / paired tumor / Cancer / tumors / IV disease / dysphagia / chills / folliculitis / metastatic colorectal cancer / mucositis / allergy / fever / extensive tumor / locoregional squamous cell carcinoma / macroscopic disease / nimotuzumab reduced tumor / incisional primary tumor / stable disease / skin tumors / Unresectable Squamous Cell Carcinoma / malignant gliomas / respiratory disease / rash / disorders / primary tumor / /
National Institute of Oncology and Radiobiology / Autonomous University of Barcelona / SENDO Foundation / 2Pathology Service / Center for State Control of Quality of Drugs / Medical Oncology Service / Center of Molecular Immunology / 7National Institute of Oncology and Radiobiology / 6Pathology Service / American Association for Cancer Research / Ethics Committee / 3Medical Oncology Service / /
Person
IVA SCCHN / Kim R. Incidence / Fundació Privada Cellex / Salud Carlos III / / /
Position
inoperable head / RT / locally advanced head / Switzerland Corresponding Author / advanced head / Representative / /